Changeflow GovPing Government & Legislation Scottish Dental Guidance Restricts Amalgam Use ...
Routine Notice Added Final

Scottish Dental Guidance Restricts Amalgam Use in Patients

Favicon for www.regulations.gov Regulations.gov Final Notices
Detected
Email

Summary

A regulatory filing has been made to the FDA on regulations.gov under docket FDA-2026-P-4271-0091, referencing Scottish guidance that restricts the use of dental amalgam in patients. The document filing date and specific regulatory outcome are not visible in the restricted content. This submission may be relevant to ongoing US regulatory considerations regarding mercury-containing dental filling materials.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

This feed pulls every final notice posted to regulations.gov across all federal agencies, around 240 a month. Final notices are the binding step in the federal rulemaking cycle: a final rule, a no-action determination, a self-regulatory organization rule change, or a procedural notice that takes effect on publication. Watch this for the actionable end of the rulemaking pipeline rather than the proposed-and-comment phase. GovPing publishes each notice with the issuing agency, docket ID, effective date where stated, and document type. Recent examples include Nasdaq ISE auction rule changes and an NYSE proposal enabling tokenized securities trading under the DTC pilot.

What changed

A regulatory submission has been filed with the FDA referencing Scottish guidance that restricts dental amalgam use in patients. The full contents of the guidance are restricted due to copyright. Dental amalgam, a mercury-containing material historically used in dental fillings, has faced increasing regulatory restrictions globally as part of mercury phase-down commitments.

Affected parties in the US dental and medical device sectors should monitor this filing, as it may indicate increased regulatory scrutiny or potential similar restrictions on dental amalgam use domestically. Healthcare providers performing dental procedures and manufacturers of dental filling materials should review current practices and any applicable FDA guidance on mercury-containing dental products.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Content Restricted

Reason Restricted: Copyrighted

Get daily alerts for Regulations.gov Final Notices

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Substantive
Docket
FDA-2026-P-4271-0091

Who this affects

Applies to
Healthcare providers Medical device makers Patients
Industry sector
6211 Healthcare Providers
Activity scope
Dental procedures Medical device regulation Mercury materials
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Healthcare
Topics
Medical Devices Public Health

Get alerts for this source

We'll email you when Regulations.gov Final Notices publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!